IP Library Granted Patent US 9,593,384
Granted Patent B2
US 9,593,384 · App. 14/258,339 · Granted Mar 14, 2017

Metronidazole resistance in trichomonas vaginalis and single nucleotide polymorphisms

Inventors: David W Hilbert (Burlington, NJ); Scott E Gygax (Yardley, PA); Martin E. Adelson (East Windsor, NJ); Eli Mordechai (Robbinsville, NJ); Jessica Schuyler (Burlington, NJ); Teresa Paulish-Miller (Yardley, PA)
Assignee: Medical Diagnostic Laboratories, LLC
C12Q1/6895C12Q1/689C12Q1/6869C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,593,384
App. No.
14/258,339
Granted
Mar 14, 2017
Kind
B2
Abstract

The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis . The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis . The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.

Claims (9)

1. A kit for detecting metronidazole resistance in Trichomonas vaginalis in a human, comprising:

(a) one or a plurality of reagents for detecting the presence of A238T in tvntr6 in Trichomonas vaginalis present in a human, wherein the reagent or plurality of reagents comprises a fluorescently labeled probe consisting of SEQ ID NO: 7; and

(b) an instruction for use of the reagent or a plurality of reagents in detecting the presence of A238T in trntr6 in Trichomonas vaginalis , wherein the presence of A238T in trntr6 in Trichomonas vaginalis is indicative metronidazole resistance in Trichomonas vaginalis.

2. The kit of claim 1 , wherein the plurality of reagents comprises a forward primer consisting of SEQ ID NO 5 and a reverse primer consisting of SEQ ID NO 6.

3. The kit of claim 1 , wherein the plurality of reagents comprises a probe consisting of SEQ ID NO: 11, a forward primer consisting of SEQ ID NO: 9 and a reverse primer consisting of SEQ ID NO: 10.

4. The kit of claim 1 further comprising a reagent for isolating nucleic acid.

5. The kit of claim 1 further comprising a reagent for allele-specific PCR and sequencing.

6. The kit of claim 1 further comprising a reagent for PCR and pyrosequencing.

7. The kit of claim 1 , wherein the plurality of reagents comprises a fluorescently labeled probe comprising a nucleic acid sequence consisting of SEQ ID NO 11.

Assignments (4)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (3)
Division 13680553 · Nov 19, 2012
Provisional Application 61629661 · Nov 23, 2011
Related Publication 20140377749A1 · Dec 25, 2014